New hope drug enters human testing for Tough-to-Treat cancers
NCT ID NCT07112222
Summary
This is the first study in people testing a new drug called LM-350 for advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how the body handles the drug. Researchers will also check for early signs that the drug might help shrink tumors in up to 80 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Cancer Care Wollongong Pty Limited
RECRUITINGWollongong, New South Wales, Australia
Contact
-
Cancer Research SA
RECRUITINGAdelaide, South Australia, Australia
Contact
-
Peninsula and South Eastern Haematology and Oncology Group
RECRUITINGFrankston, Victoria, Australia
Contact
Conditions
Explore the condition pages connected to this study.